Search clinical trials for: AMG 162

Total 5553 results

Amgen

Completed

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer
Hanmi Pharmaceutical Company Limited

Completed

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet (PGP inhibitor)

Healthy

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm

United States
Hope Rugo, MD
University of California, San Francisco; Amgen

Terminated

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Early Stage Breast Cancer

United States
Amgen

Completed

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral Density
Amgen

Completed

Study of Transitioning From Alendronate to Denosumab

Postmenopausal Osteoporosis
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Amgen

Completed

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Belgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
GeneScience Pharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

China
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Zydus Therapeutics Inc.

Completed

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis (EVIDENCES VI)

Non Alcoholic Steatohepatitis

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Philip Morris Products S.A.

Completed

Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it

Pharmacokinetics

Russian Federation
Amgen

Terminated

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus | Lupus

United States, Australia, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | MET Positive

United States
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
Amgen

Completed

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Asthma

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Taiwan, Korea, Republic of, Japan
Amgen

Completed

Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Gastrointestinal Cancer
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Xentria, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

Healthy Participants

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Amgen

Completed

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Amgen

Completed

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Glioblastoma or Malignant Glioma

United States, Australia, Netherlands, Germany, Spain, France
M.D. Anderson Cancer Center
Array BioPharma

Terminated

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Leukemia

United States
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Duramed Research

Completed

A Safety Extension Study of DR-OXY-301

Overactive Bladder

United States
Amgen

Completed

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MP-214 in Patients With Schizophrenia

Schizophrenia

Taiwan, Korea, Republic of, Japan
EnnovaBio Australia Pharmaceuticals Pty Ltd

Completed

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

Healthy

Australia
Amgen

Recruiting

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Spain, Australia, Germany, France, Japan, Canada
Amgen

Available

AMG 714 Expanded Access Program

Celiac Disease
Amgen

Terminated

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, Taiwan, Spain, Austria, United States, France, Japan, Germany, Netherlands
Amgen

Terminated

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (AMG420)

Relapsed and/or Refractory Multiple Myeloma

United States, Japan, Belgium, Australia, Switzerland
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Daewoong Pharmaceutical Co. LTD.

Completed

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
Kartos Therapeutics, Inc.

Completed

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Cancer | Glioblastoma | Multiple Myeloma | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States, France, Netherlands
Cytokinetics

Completed

Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency

Heart Failure

United States
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

Psoriasis

Australia, New Zealand
Amgen

Terminated

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Stomach Neoplasms

Belgium, France, Italy, Spain, Czechia, Poland, United States, Korea, Republic of, Russian Federation, Canada, United Kingdom, Australia, Austria, Germany, Hungary, Greece, Peru, Chile
Amgen

Completed

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Cancer | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Thrombocytopenia | Oncology | Chemotherapy-Induced Thrombocytopenia
TaiwanJ Pharmaceuticals Co., Ltd

Terminated

Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies (JKB122)

Chronic Hepatitis C

Taiwan
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Beijing Shenogen Biomedical Co., Ltd
307 Hospital of PLA; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China
Hanlim Pharm. Co., Ltd.

Completed

The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca

Healthy Male Volunteers

Korea, Republic of
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
Amgen

Completed

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Belgium, Spain, Australia
Amgen

Active, not recruiting

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Non-squamous Non-small Cell Lung Cancer | Epithelial Ovarian Cancer | Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors

United States, Australia, Switzerland
Xencor, Inc.

Terminated

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States, Australia

Search clinical trials for: AMG 162

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations